ADMA Biologics, Inc.

ADMA · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income$36,429$34,218$26,904$111,896
Dep. & Amort.$2,023$2,058$2,159$2,163
Deferred Tax$4,803$1,620$0$0
Stock-Based Comp.$5,047$4,963$4,624$5,433
Change in WC-$37,320-$23,004-$56,893$9,781
Other Non-Cash$2,311$1,284$3,531-$79,057
Operating Cash Flow$13,293$21,139-$19,675$50,216
Investing Activities
PP&E Inv.-$14,368-$2,422-$4,701-$2,757
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0-$105-$19$7
Investing Cash Flow-$14,368-$2,527-$4,720-$2,750
Financing Activities
Debt Repay.-$3,274-$450$0-$30,000
Stock Issued$389$2,064$0$0
Stock Repurch.-$23,038$0-$7,228-$644
Dividends Paid$0$0$0$0
Other Fin. Act.-$1,902-$1,566$101-$382
Financing Cash Flow-$27,825$48-$7,127-$31,026
Forex Effect$0$0$0$0
Net Chg. in Cash-$28,900$18,660-$31,522$16,440
Supplemental Information
Beg. Cash$90,285$71,625$103,147$86,707
End Cash$61,385$90,285$71,625$103,147
Free Cash Flow-$1,075$18,717-$24,376$47,459